What were the sale prices for Zhenyu Xu’s SOPH share transactions?

The reported prices are weighted averages: $7.9427 per share on August 19, $8.4078 on August 20, and $8.4036 on August 21. Each reflects multiple trades within ranges of $7.90–$8.01 and $8.40–$8.43 (or $8.40–$8.42), respectively.

Does the Form 4 disclose Xu’s SOPH share holdings after these sales?

No resulting holdings are provided in the non-derivative transaction rows; the total shares following transaction fields for these sales are left blank in the Form 4 data shown.

SOPHiA GENETICS CSO sells 20,000 shares under plan

Q: What insider transactions did SOPH report for Zhenyu Xu on this Form 4?

The Form 4 reports that Chief Scientific Officer Zhenyu Xu sold a total of 20,000 Ordinary Shares of SOPHiA GENETICS SA in three transactions on August 19, 20, and 21, 2026, in open-market or private sales.

Q: How many SOPH shares did Zhenyu Xu sell and on which dates?

Zhenyu Xu sold 10,000 SOPH Ordinary Shares on August 19, 2026, 4,592 shares on August 20, 2026, and 5,408 shares on August 21, 2026, for a total of 20,000 shares sold.

Q: What type of security did Zhenyu Xu sell in SOPH?

All reported transactions involve Ordinary Shares of SOPHiA GENETICS SA, sold in open-market or private transactions as indicated by transaction code S and its description.

SOPHiA GENETICS SA (SOPH) reported that Chief Scientific Officer Zhenyu Xu sold a total of 20,000 Ordinary Shares in open-market or private transactions under a duly adopted Rule 10b5-1(c) trading plan.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

SOPHiA GENETICS SA (SOPH) reported that Chief Scientific Officer Zhenyu Xu sold a total of 20,000 Ordinary Shares in open-market or private transactions under a duly adopted Rule 10b5-1(c) trading plan. The sales occurred on August 19–21, 2026, at weighted average prices of $7.94, $8.41, and $8.40, each representing multiple trades within narrow price ranges.

Insider Trade Summary 10b5-1

Net Seller: 20,000 shares

Net Sell 3 txns

Insider Xu Zhenyu

Role Chief Scientific Officer

Sold 20,000 shs ($163K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares ^{F1, F4}	5,408	$8.4036	$45K
Sale	Ordinary Shares ^{F1, F3}	4,592	$8.4078	$39K
Sale	Ordinary Shares ^{F1, F2}	10,000	$7.9427	$79K

Holdings After Transaction: Ordinary Shares — 566,887 shares (Direct)

Footnotes (4)

F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.90 to $8.01, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.40 to $8.43, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.40 to $8.42, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Total shares sold: 20,000 Ordinary Shares Shares sold on 2026-08-19: 10,000 Ordinary Shares Shares sold on 2026-08-20: 4,592 Ordinary Shares +4 more

7 metrics

Total shares sold 20,000 Ordinary Shares Aggregate of three open-market or private sales by CSO Zhenyu Xu

Shares sold on 2026-08-19 10,000 Ordinary Shares Sale by Zhenyu Xu at weighted average price of $7.9427

Shares sold on 2026-08-20 4,592 Ordinary Shares Sale by Zhenyu Xu at weighted average price of $8.4078

Shares sold on 2026-08-21 5,408 Ordinary Shares Sale by Zhenyu Xu at weighted average price of $8.4036

Price range on 2026-08-19 $7.90–$8.01 per share Multiple transactions; weighted average reported in Column 4

Price range on 2026-08-20 $8.40–$8.43 per share Multiple transactions; weighted average reported in Column 4

Price range on 2026-08-21 $8.40–$8.42 per share Multiple transactions; weighted average reported in Column 4

Key Terms

Rule 10b5-1(c), weighted average price, Ordinary Shares, open market or private transaction

4 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Ordinary Shares financial

"security_title: "Ordinary Shares" for each transaction"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

open market or private transaction financial

"transaction_code_description: "Sale in open market or private transaction""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did SOPH report for Zhenyu Xu on this Form 4?

The Form 4 reports that Chief Scientific Officer Zhenyu Xu sold a total of 20,000 Ordinary Shares of SOPHiA GENETICS SA in three transactions on August 19, 20, and 21, 2026, in open-market or private sales.

How many SOPH shares did Zhenyu Xu sell and on which dates?

Zhenyu Xu sold 10,000 SOPH Ordinary Shares on August 19, 2026, 4,592 shares on August 20, 2026, and 5,408 shares on August 21, 2026, for a total of 20,000 shares sold.

Were the reported SOPH insider sales by Zhenyu Xu under a Rule 10b5-1 plan?

Yes. A footnote states that each transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c), and the Form 4’s Rule 10b5-1 checkbox is affirmed.

What type of security did Zhenyu Xu sell in SOPH?

All reported transactions involve Ordinary Shares of SOPHiA GENETICS SA, sold in open-market or private transactions as indicated by transaction code S and its description.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 08/21/2026 - 04:01 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xu Zhenyu

(Last)

(First)

(Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE

1180

(City)

(State)

(Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	08/19/2026		S		10,000⁽¹⁾	D	$7.9427⁽²⁾	576,887	D
Ordinary Shares	08/20/2026		S		4,592⁽¹⁾	D	$8.4078⁽³⁾	572,295	D
Ordinary Shares	08/21/2026		S		5,408⁽¹⁾	D	$8.4036⁽⁴⁾	566,887	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.90 to $8.01, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.40 to $8.43, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.40 to $8.42, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Zhenyu Xu	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR